Pan-tumor multicenter study of the impact of prior immune-related adverse events (irAEs) on safety and efficacy of subsequent antibody-drug conjugate (ADC)
Date:
Poster showing that prior irAEs during ICI therapy were associated with increased ADC toxicity across tumor types.